Open access
Open access
Powered by Google Translator Translator

General Hematology

Editorial: Prophylactic anticoagulation for patients in hospital with covid-19

23 Feb, 2021 | 01:59h | UTC

Prophylactic anticoagulation for patients in hospital with covid-19 – The BMJ

Related: Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials AND Cohort study: Early initiation of prophylactic anticoagulation linked to reduced mortality in patients admitted to hospital with Covid-19

 


COVID‐19 convalescent plasma: Interim recommendations from the AABB

19 Feb, 2021 | 02:56h | UTC

COVID‐19 convalescent plasma: interim recommendations from the AABB – Transfusion

News release: AABB panel issues interim recommendations for Covid-19 convalescent plasma use

 


M-A: The effect of convalescent plasma therapy on COVID-19 patient mortality

18 Feb, 2021 | 03:07h | UTC

The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis – Mayo Clinic Proceedings

Related study (not published yet) with conflicting results: RECOVERY trial: No Benefit from convalescent plasma in hospitalized patients with Covid-19 (news release and commentary)

 


COVID-19: A Hematologist’s Perspective

17 Feb, 2021 | 01:35h | UTC

Coronavirus Disease 2019 (COVID-19): A Haematologist’s Perspective – Acta Haematologica

Editorial: A Haematologist’s Guide to Coronavirus Disease 2019: Encyclopaedia or Doorstop?

 


ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

15 Feb, 2021 | 00:49h | UTC

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer – Blood Advances

Commentary: ASH 2021 Guidelines for Prevention and Treatment of Venous Thromboembolism in Patients With Cancer – The ASCO Post

 


Cohort study: Early initiation of prophylactic anticoagulation linked to reduced mortality in patients admitted to hospital with Covid-19

15 Feb, 2021 | 01:18h | UTC

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study – The BMJ

Commentaries: Preventive blood thinning drugs could reduce COVID hospital deaths – London School of Hygiene & Tropical Medicine AND Preventive blood thinning drugs linked to reduced risk of death in COVID-19 patients – The BMJ AND Expert reaction to a study looking at prophylactic anticoagulants as a treatment for hospitalised patients with COVID-19 – Science Media Centre AND

 

Commentary on Twitter

 


RCT: Among patients with acute MI and anemia, a restrictive transfusion strategy resulted in a noninferior rate of major cardiovascular events compared to a liberal transfusion strategy

10 Feb, 2021 | 01:39h | UTC

Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial – JAMA (free for a limited period)

Commentary: Restrictive vs. Liberal Blood Transfusion Strategy for MI and Anemia – American College of Cardiology

 

Commentary on Twitter

 


Thrombosis and COVID-19: Controversies and (Tentative) Conclusions

9 Feb, 2021 | 01:41h | UTC

Thrombosis and COVID-19: Controversies and (Tentative) Conclusions – Clinical Infectious Diseases

 

Commentary on Twitter

 


Case report: SARS-CoV-2 evolution in immunocompromised patient treated with convalescent plasma

7 Feb, 2021 | 21:32h | UTC

SARS-CoV-2 evolution during treatment of chronic infection – Nature

 

Commentary on Twitter

 


ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

3 Feb, 2021 | 01:07h | UTC

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease – Blood

 


[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials

1 Feb, 2021 | 01:58h | UTC

Full-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)

Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial

News release: Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients – National Institutes of Health

 


Cohort study: Long-term clinical outcomes of hematopoietic stem cell transplantation in 210 patients with multiple sclerosis

25 Jan, 2021 | 01:15h | UTC

Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis – Neurology (link to abstract – $ for full-text)

 


Stay Updated in Your Specialty

No spam, just news.